Navigation Links
Concerta, Drug Used in ADHD Treatment Less Likely To Result In Abuse

A research team has now established that a delayed-release stimulant, used for treatment of attention-deficit hyperactivity disorder (ADHD) may be associated with less abuse, when compared to other stimulant drugs//. Therapeutic doses of Concerta (methylphenidate) in the form of an oral formulation have not been reported to produce subjective effects that may lead to drug abuse. The results of the study can be found in the American Journal Of Psychiatry.

It has been known from previous studies and pharmacological research that drugs that cause euphoria may lead to abuse. This however requires rapid delivery of the drug formulation to the brain. The researchers of the present study examined the delivery of two different formulations of methylphenidate and compared the abuse potential of the formulations.

Drugs such as methylphenidate, commonly given for treatment of ADHD act by inhibition of dopamine transporter. This molecule accounts for increased levels of the neurotransmitter in the brain. ADHD patients lose control over movement, behaviour and attention, as their brains do not regulate the dopamine levels effectively. Such stimulant drugs though provide control of ADHD symptoms, do have the potential of being abused.

A quick release, traditional drug formulation was compared to slow release formulation (Concerta) that is released over a 12 hour period, to precipitate a gradual increase in blood levels. 12 healthy individuals (no diagnosis of ADHD) were recruited for the present study and received either of the medications on a random basis. The study participants received drug dosages high enough to produce similar peak levels in both brain and the blood.

Positron emission tomography (PET scans) was taken before and after the test. In addition, the study participants were required to take up blood tests and fill up questionnaires regarding awareness of drug effects and whether they enjoyed or disliked those effect
'"/>




Page: 1 2

Related medicine news :

1. Advances in Treatment of Cataracts
2. Recommendations for Treatment of Blood Pressue
3. Treatment for Menieres disease
4. Treatment for pre-menstrual syndrome is ineffective
5. Better Treatment for obesity
6. Gene Treatment for Heart Disease
7. More People Seeking Treatment for Depression
8. Focused Treatment For Childhood Cancer
9. Inadequate Drug Treatment For Youth
10. FDA Approves New surgery Treatment for Farsightedness
11. Treatment of antibiotics ineffectual in bronchitis
Post Your Comments:
(Date:12/2/2008)... As the International Day ... Ships celebrates with the story of a young boy bo...ies onboard the Africa Mercy, a floating hospital ...ow and he can run and play with the other children...e downloaded at www.mercyshipsnewsroom.org , ...
(Date:12/2/2008)... Orion Health announces th... (SEARHC) of Juneau, Alaska, has selected the Rhap...nt electronic health record, radiology, pharmacy, ...each other. It also plans to extend connectivity t...Alaska immunization registry) and AKAIMS (an MIS a...
(Date:12/2/2008)...ARIS, Dec. 2 Motorola, I...plemented its T2 powerbroadband system to enable,...e healthcare provider,Generale de Sante to deliv...,Motorola solution provides an advanced IP broadba...delivered over the existing telephone line, elimin...
(Date:12/1/2008)...OUTH BEND, Ind., Dec. 2 Patient sa...ities are on the rise according to a new report,f...ent Pulse Report: Patient,Perspectives on America...acilities as a driver for improvement in patient s... than 2 million patients treated at more than,1,2...
Breaking Medicine News(10 mins):Health News:Mercy Ships Recognizes International Day of Disabled Persons 2Health News:Mercy Ships Recognizes International Day of Disabled Persons 3Health News:SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring 2Health News:SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring 3Health News:Motorola Extends the Delivery of Personalized Media Experiences to Hospital Group Generale De Sante 2Health News:Motorola Extends the Delivery of Personalized Media Experiences to Hospital Group Generale De Sante 3Health News:Outpatient Service Facilities Face Increasing Competition - Patient Perceptions More Important Than Ever 2
...es Inc. today announced that Mylan Pharmaceuticals.... Food and Drug Administration (FDA) for its Abbr... Hydrochloride Extended-release Tablets, 12.5 mg a...o receive final approval on June 29, 2007, concurr...
...report released today documents the explosive grow...t more than 200 million people are now protected b...nd public places. The report concludes that the mo...accelerating because a global treaty ratified by 1...
...Technologies, Inc. (NTI) announced today the prese...l trials of ancrod and updates on the clinical de...TM) (ancrod), for the treatment of acute ischaemic...ss in Glasgow, Scotland in the United Kingdom. Vip...
... the number two killer in our nation, Americans ar...n fact, according to a recent nationwide survey sp... the scientific community is winning the war again...arching new options to fight cancer, Abbott is ho...
Other Medicine News:Health News:Growth of Smoke-Free Air Laws Worldwide; More Than 200 Million Found "Fully Protected" 2Health News:Investigational Drug Being Pursued for the Treatment of Ischaemic Stroke 2Health News:Americans Optimistic About the War on Cancer 2
(Date:11/26/2008)... , FRANKLIN, Mass., Nov. 26 /PRNewswire-Firs...CSF) announced today that it has received full app...FDA) for its U.S. pivotal trial to study the effec...nd associated therapy in the prevention of Contras...so approved PLC,s request to expand their investig...
(Date:11/25/2008)...ire-USNewswire/ -- Kleinert Kutz and University o...S. hand transplant on Messina, New York resident, ...al Hand Care Center on Monday, November 24. The i...leted shortly after 9 p.m. in a record nine hours....in/prnh/20081125/DC48555-a ) , (Photo: http:/...
(Date:11/25/2008)... 25 Proteolix, Inc., a,leader in ...s that target,protein degradation pathways in can... data from two ongoing Phase 2 clinical trials of ... at the upcoming 50th Annual Meeting of the,Ameri...he first in a new class,of specific proteasome in...
(Date:11/25/2008)...swire-FirstCall/ -- Pharmacyclics, Inc.,(Nasdaq: ...leted a Phase 1,clinical trial with PCI-27483, th...Factor VIIa inhibitor. The trial was conducted in ...afety and pharmacologic effect of,PCI-27483. A si...ear dose,response in the International Normalized...
Breaking Medicine Technology:PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 4Kleinert Kutz Hand Surgeons Perform Fifth U.S. Hand Transplant in Record Time at Jewish Hospital Hand Care Center 2Kleinert Kutz Hand Surgeons Perform Fifth U.S. Hand Transplant in Record Time at Jewish Hospital Hand Care Center 3Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 2Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 3Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 2Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 3Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 4Siemens Soarian Health Information Management is Widely Adopted by Leading Healthcare Institutions in 2007 3089 1Siemens Soarian Health Information Management is Widely Adopted by Leading Healthcare Institutions in 2007 3089 2Siemens Soarian Health Information Management is Widely Adopted by Leading Healthcare Institutions in 2007 3089 3Siemens Soarian Health Information Management is Widely Adopted by Leading Healthcare Institutions in 2007 3089 4Consumer Safety Alert on Fat Dissolving Injections 3086 1Consumer Safety Alert on Fat Dissolving Injections 3086 2Consumer Safety Alert on Fat Dissolving Injections 3086 3N V Perricone M D Cosmeceuticals Elevates Role of Christina Banas to Executive Director Global Communications 3083 1N V Perricone M D Cosmeceuticals Elevates Role of Christina Banas to Executive Director Global Communications 3083 2Anaptys Biosciences Appoints R Scott Greer to Board of Directors 1119 1Anaptys Biosciences Appoints R Scott Greer to Board of Directors 1119 2
...-May 10, 2007 - According to,The Waismann Method 2...respondents seeking treatment for opiate dependenc...icodin, OxyContin, Percocet,and Fentanyl were amon...mothers who reported a dependency said they suffer...egistered addiction,specialist for the Waismann Me...
...oping Therapies to Prevent,and Reverse Atheroscler...07 /PRNewswire/ -- KineMed, Inc.,a pathway-based ...today the first method for measuring the efflux of...athway known as reverse cholesterol,transport (RCT...,cholesterol can be removed from tissues and has t...
Other Medicine Technology:Waismann Method Survey Reveals 65 Percent of Women Seeking Opiate,Dependency Treatment Are Mothers 2KineMed Presents Data Measuring Changes in Reverse Cholesterol,Transport for the First Time 2KineMed Presents Data Measuring Changes in Reverse Cholesterol,Transport for the First Time 3
Set of 5 large bone curettes. One each of the following: angled small, straight small, angled medium, straight medium, and angled large.
Rasp with down cutting pattern.
Designed for proximal femoral elevation in total hip replacement or in other surgery with a similar need for bone manipulation.
Beuse Zygomatic Arch Awl with slightly curved tip.
Medicine Products: